← All trials
NCT04932824
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 19, 2021
- Primary completion
- May 31, 2023
- Completion date
- Sep 14, 2023
- First posted
- Jun 21, 2021
- Last posted
- Jun 21, 2021
- Enrollment
- 150
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Clover BiopharmaceuticalsLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.